Challenges associated with treatment of anemia in difficult-to-manage patients with anemia of CKD Inflammation Diabetes Cancer Patients who are Patients that have hospitalized received a kidney • Acute inflammation can •Prevalence of anemia in higher • Transfusions can lead to transplant reduce response to iron and in patients with DKD than complication but necessary • Difficulties in transition of ESA therapy nondiabetic CKD in some patients care from nephrologists to •Post-transplant anemia has a hospitalist high prevalence and increase the •Anemia has earlier onset and is • ESA therapy can increase risk of death, loss if graft more severe risk of tumor progression, • Anemia can increase length function, congestive heart failure VTE, and death of hospitalization •Increased subclinical •High dose ESA does not improve inflammation • No guideline for ESA use in • Hb levels decrease during short term allograft function anemic CKD patients with and after hospitalization •Clinical inertia regarding cancer with prolonged recovery •Long term low dose ESA may initiating anemia management prevent progression of allograft nephropathy
Kidney Dis 2022;8:103–114
Challenging Topics Hb target Iron EPO HIF stabilizers
EXPERT OPINION ON PHARMACOTHERAPY 2022, VOL. 23, NO. 1, 19–
Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors • Roxadustat was approved in China in 2018 and 2019 in DD and NDD adult patients, respectively. • In Japan, Roxadustat was approved in 2019 and 2020 in DD and NDD, respectively. • Enarodustat was approved in Japan 2020 Nephrology. 2021;26:105–118.
Nephrology. 2021;26:105–118.
Nephrology. 2021;26:105–118.
Nephrology. 2021;26:105–118.
Takkavatakarn et al (submission, unpublished)
Takkavatakarn et al (submission, unpublished)
The efficacy and safety of roxadustat for the treatment of anemia in non-dialysis dependent chronic kidney disease patients: An updated systematic review and meta-analysis of randomized clinical trial PLOS ONE | https://doi.org/10.1371/journal.pone.0266243 April 1, 2022
Am J Nephrol 2022;53:366–371
Am J Nephrol 2022;53:366–371
Am J Nephrol 2022;53:366–371
Am J Nephrol 2022;53:366–371
Am J Nephrol 2022;53:361–365
Am J Nephrol 2022;53:366–371
Thank you
Search
